NCT04519424View on ClinicalTrials.gov

CSL324 in COVID-19

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

September 30, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

May 31, 2021

Conditions

Coronavirus Disease 2019 (COVID-19)

Interventions

BIOLOGICAL

CSL324

Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody

DRUG

Placebo

Normal saline (0.9% sodium chloride)

Sponsors

Lead Sponsor

All Listed Sponsors

lead

CSL Behring

INDUSTRY

NCT04519424 - CSL324 in COVID-19 | Biotech Hunter | Biotech Hunter